Services
Sustainable Impact Modeling

Our goal is to help enterprises to achieve a sustainable development, to find the right balance between resilience, efficiency and innovation. We give support to companies and organization focused on sustainable strategic development, in terms of profitability, ethical behavior, social justice and environment.

Furthermore, within the food supplements, functional foods, novel foods, nutraceuticals, cosmetics and medical devices markets, we design and develop Your innovative business models according to UN Sustainable Development Goals and guidance.


Our distinguishing competency is the ability to work within complex systems and to model strategic and operational business solutions in a very short time, activating a vast range of creative and scientific techniques, collaborative innovation methods, management knowledge and specific sector competencies.

BLYMUM approach exploits business modeling based upon modular systems that are both product-oriented and people-oriented and their combinations: found on the Sustainable Value Innovation methodology (SVI-ALDEHYDE MBS®, by CINNAM SRL) and aimed at contributing to the harmony between the company’s internal and external environment, people’s wellness, business development and the overall sustainable economic and human growth.

Livella®, our distinctive methodology to health and wellbeing improvement, is regularly adopted for Sustainable Impact Modeling.

PRINTABLE PAGE FURTHER RESOURCES (RESERVED AREA) SHARE THIS PAGE

Share this page with a friend

Your name

Your email address

Your friend's name

Your friend's email address


I've read and accept the Privacy Policy


POSTS
31/01/2023
Regulation (EU) no. 536/2014 on Clinical Trials
After the transition period, from today's date 31 January 2023 all the authorization procedures for clinical trials must compulsorily be requested following the contents of the new...
read more
22/11/2022
Market Surveillance of Medical Devices
All manufacturers of medical devices (MDs) must minimize the risk posed by their MDs and ensure patient safety. Post-market surveillance is thus mandatory. According to the new MDR...
read more